How much is the acute kidney injury market worth, and how is it expected to expand?
The acute kidney injury market size has grown strongly in recent years. It will grow from $5.37 billion in 2024 to $5.74 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, growing incidence of hospital-acquired infections, increasing awareness about kidney health, and advancements in critical care medicine.
The acute kidney injury market size is expected to see strong growth in the next few years. It will grow to $7.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to the rising prevalence of sepsis, growing demand for personalized treatment, increasing government healthcare initiatives, rising healthcare expenditure in emerging markets, and a high focus on personalized medicine and regenerative therapies. Major trends in the forecast period include wearable dialysis devices, artificial intelligence in treatment optimization, portable renal replacement therapy systems, continuous renal replacement therapy (CRRT) advancements, remote monitoring, and telemedicine integration.
Get Your Free Sample of The Global Acute Kidney Injury Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21079&type=smp
Which industry factors have accelerated the acute kidney injury market’s expansion?
Increased prevalence of diabetes is expected to propel the growth of the acute kidney injury market going forward. Diabetes refers to a group of metabolic diseases characterized by high blood sugar levels, either due to the body’s inability to produce enough insulin or because cells do not respond properly to insulin. The increasing prevalence of diabetes is driven by factors such as rising obesity rates, poor diets, sedentary lifestyles, aging populations, and enhanced awareness and diagnosis. Acute kidney injury triggers metabolic and inflammatory changes that can influence insulin resistance and glucose homeostasis, highlighting a complex interplay that may impact diabetes progression and management. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, increased prevalence of diabetes is driving the growth of the acute kidney injury market.
What are the primary segments of the acute kidney injury market?
The acute kidney injury market covered in this report is segmented –
1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury
2) By Treatment Type: Dialysis, Drug Therapy, Urinary Implants
3) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome
2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract
3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report
Which firms are leading the acute kidney injury market?
Major companies operating in the acute kidney injury market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co. Ltd., Teva Pharmaceutical Industries Ltd., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., Alexion Pharmaceuticals Inc., Alloksys Life Sciences B.V., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB
Which market trends are set to define the future of the acute kidney injury market?
Major companies operating in the acute kidney injury (AKI) market are focusing on obtaining regulatory approvals to enhance their product portfolios and offer novel treatment options. Regulatory approvals refer to the official authorization granted by regulatory bodies, such as the FDA or EMA, allowing a product to be marketed and sold after meeting safety, efficacy, and quality standards. For instance, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology company, received FDA approval to initiate a Phase II clinical trial for its lead asset, MTX652, targeting acute kidney injury (AKI) in patients at high risk following cardiac surgery. It is designed to target critical pathways involved in kidney injury and repair, aiming to reduce inflammation, prevent further kidney damage, and promote recovery. Its unique feature of this trial is its focus on leveraging novel therapeutic mechanisms to address the underlying molecular causes of AKI, which could offer more effective treatment options compared to existing interventions. The Phase II trial will evaluate MTX652’s safety, efficacy, and pharmacokinetics, providing crucial data that could support broader clinical adoption and potential approval.
Which geographic trends are shaping the acute kidney injury market, and which region has the highest market share?
North America was the largest region in the acute kidney injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Acute Kidney Injury Market Report 2025 Offer?
The acute kidney injury market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Acute kidney injury (AKI) refers to a sudden decline in kidney function, leading to an accumulation of waste products, electrolytes, and fluids in the body. It can develop rapidly over hours or days and is often caused by conditions like reduced blood flow, direct kidney damage, or obstruction of the urinary tract.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21079
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
